Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The facility will manufacture its Herceptin biosimilar, Tuznue
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Subscribe To Our Newsletter & Stay Updated